Do Traders Think Dr Reddy's Laboratories Ltd (RDY) Can Keep Climbing Tuesday?

Dr Reddy's Laboratories Ltd (RDY) stock has risen 1.21% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator.

Dr Reddy's Laboratories Ltd has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on RDY!

See Full RDY Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With RDY Stock Today?

Dr Reddy's Laboratories Ltd (RDY) stock is trading at $55.04 as of 12:15 PM on Tuesday, Jun 21, an increase of $1.83, or 3.44% from the previous closing price of $53.21. The stock has traded between $54.42 and $55.21 so far today. Volume today is low. So far 34,984 shares have traded compared to average volume of 206,759 shares. To see InvestorsObserver's Sentiment Score for Dr Reddy's Laboratories Ltd click here.

More About Dr Reddy's Laboratories Ltd

Headquartered in India, Dr. Reddy's Laboratories develops and manufactures generic pharmaceutical products sold across the world. The company specializes in low-cost, easy-to-produce small-molecule generic drugs and active pharmaceutical ingredients. Its drug portfolio in recent years has included biosimilar drug launches in select emerging markets and has shifted toward injectables and more complex generic products. Geographically, the company's sales are well dispersed across North America, India, and other emerging markets. Click Here to get the full Stock Report for Dr Reddy's Laboratories Ltd stock.